COX-2 inhibitors
Recently the COX-2 inhibitor Vioxx was withdrawn in the UK and the US. Now, concerns are being raised about another COX-2:
Pfizer Inc. on Friday said its popular Celebrex arthritis drug more than doubled the risk of heart attack in a large cancer-prevention trial, a setback that comes just weeks after Merck & Co. recalled its similar Vioxx drug due to heart safety risks.
…
“This does not bode well for COX-2 inhibitors in general,” Ira Loss, an analyst at Washington Analysis, said of the Celebrex trial results. “The sense had been that Celebrex is somehow different from the others.”Dr. Richard Hayes, a cardiologist at New York University, told Reuters, “This raises my concern about Celebrex and all the COX-2 inhibitors, so I will no longer be prescribing any of them.”
Via Medpundit.
1 Comment
RSS feed for comments on this post.
Cardiovascular risk and COX-2 inhibition in rheumatological practice.
Cox-2 inhibitors are in the news having now heard concerns over both Vioxx and Celebrex. So it seems appropriate to look at a recent article on Cox-2’s – no light bulbs in this one but enough information to justify a conservative approach to utilizing…